Enlivex Therapeutics Ltdis A Clinical Stage Biopharmaceutical Company Based In Ness Zionaisraelfounded In 2005The Company Specializes In Developing Macrophage Reprogramming Immunotherapies Aimed At Treating Inflammatory Diseasesits Flagship Productallocetraa Cis A Universal Cell Therapy Platform Designed To Restore Immune Balanceallocetra Can Be Administered Through Systemic Intravenous Infusion Or Targeted Local Injectionsmaking It Adaptable For Various Clinical Applicationsthe Therapy Has Been Clinically Tested In Over 150 Patientsdemonstrating A Strong Safety Profile Enlivex Is Currently Advancing Allocetra Through Phase Ii Clinical Trials For Sepsis And Phase I Ii Trials For Knee Osteoarthritisthe Company S Innovative Approach Also Suggests Potential Applications In Autoimmune Conditionsenlivex Actively Engages With The Medical And Research Communityparticipating In Conferences To Share Its Findings And Progress In Macrophage Reprogramming Therapiesthe Company Is Listed On Nasdaq Under The Ticker Symbol Enlv And Employs Around 71 People
